Possible use of psilocybin in psychiatric care, including COVID-19 sequelae

This paper discuss psilocybin’s effect on the human organism and its therapeutic potential as a main or adjuvant medication for certain psychiatric diseases, more specifically, depression and anxiety, such as found in palliative care patients which are facing the end-of-life process, but also on tho...

Descripción completa

Detalles Bibliográficos
Autores: Bonifácio, Myla Chistie Araujo Custodio, Bento, Pietra Bruna Batrbosa, Trevisan, Kaynara, Pereira, Renata Cristina, Magri, Micheli Patricia de Fátima, Aversi-Ferreira, Tales Alexandre
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:Brasil
Institución:Universidade Federal de Itajubá (UNIFEI)
Repositorio:Research, Society and Development
Idioma:portugués
OAI Identifier:oai:ojs.pkp.sfu.ca:article/19259
Acceso en línea:https://rsdjournal.org/index.php/rsd/article/view/19259
Access Level:acceso abierto
Palabra clave:Psilocibina
Psiquiatria
Depressão
Ansiedade
Cuidados paliativos
Alucinógenos.
Psilocybin
Psychiatry
Depression
Anxiety
Palliative care
Hallucinogens.
Psiquiatría
Depresión
Ansiedad
Descripción
Sumario:This paper discuss psilocybin’s effect on the human organism and its therapeutic potential as a main or adjuvant medication for certain psychiatric diseases, more specifically, depression and anxiety, such as found in palliative care patients which are facing the end-of-life process, but also on those patients in which the conventional treatment was not effective. Recent studies also present the possibility of the use of psilocybin in the treatment of long-term psychiatric consequences of COVID. The available literature indicates that psilocybin promotes heightening of quality of life, modifications in the perception of self, perception of wholeness with the environment and spiritual experiences, which have great importante in the aforementioned groups of patients. Besides, it shows little to no side effects. This paper presents a review to reinforce the hypothesis of the therapeutic use of psilocybin in depression and anxiety in populations that can benefit the most of psychedelic therapy.